The Proposed EU IP Exception for Generics & Biosimilars Exports - A Cure Worse Than the Disease? (at UC Irvine)

Minssen, T. (Invited speaker)

Activity: Talk or presentation types › Lecture and oral contribution

Description

The European Union plans to introduce an SPC waiver for Generics and Biosimilars intended for export to countries without patent protection. The laudable aim is to minimize counterfeit medicines in developing countries and to promote more competition and earlier access to generics and biosimilars in Europe. But many challenges remain, including potential conflict with international treaty obligations, enforcement difficulties, and business decisions that could undermine a fundamental assumption of the new policy. This presentation will describe the proposal and discuss how it relates to US positions.

Period	8 Feb 2019
Event title	Biosimilar Innovation
Event type	Conference
Location	Irvine/LA, United States, CaliforniaShow on map
Degree of Recognition	International

Documents & Links

2019
File: application/pdf, 158 KB
Type: Text file
Abstracts
File: application/pdf, 210 KB
Type: Text file

Biosimilar Innovation Biosimiar medical products offer the promise of enhanced medical therapies at sustainable pricing. However, the scientific and economic challenges associated with biosimilars threaten to impede the promise of such medical advances. New incentive strategies are needed to advance development in this area. To address such challenges, speakers at this conference will explore the legal and regulatory frameworks needed to encourage innovative development and distribution of biosimilar products. Confirmed participants include: Dan L. Burk (UC Irvine) Michael Carrier (Rutgers University, Camden) Timo Minssen (University of Copenhagen) Jordan Paradise (Loyola University, Chicago) Nicholson Price (University of Michigan) Jacob Sherkow (NY Law School) Brenda Simon (Thomas Jefferson) Ariel Stern (Harvard Business School)